Get the Stockscreener App
3.90
8.94%
0.32
After Hours:
3.71
-0.19
-4.87%
Repare Therapeutics Inc stock is traded at $3.90, with a volume of 144.92K.
It is up +8.94% in the last 24 hours and up +4.00% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
See More
Previous Close:
$3.58
Open:
$3.75
24h Volume:
144.92K
Relative Volume:
1.46
Market Cap:
$165.54M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-26.00
EPS:
-0.15
Net Cash Flow:
$-129.10M
1W Performance:
+8.64%
1M Performance:
+4.00%
6M Performance:
+13.04%
1Y Performance:
+2.36%
1-Day Range:
$3.6006
$3.94
1-Week Range:
$3.3201
$3.94
52-Week Range:
$2.71
$8.49
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Repare Therapeutics (NASDAQ:RPTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Repare Therapeutics’ individualised anaemia management trial shows promise - Yahoo Finance
Press Release Service: Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - BioSpace
Repare Therapeutics reports progress in cancer trial - Investing.com India
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug - MSN
Dimensional Fund Advisors LP Sells 27,504 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - CRISPR Medicine News
Repare Therapeutics doses first subject in Phase I solid tumour trial - Yahoo! Voices
Repare Therapeutics begins trial for novel cancer drug By Investing.com - Investing.com Australia
Repare Therapeutics begins trial for novel cancer drug - Investing.com
Marshall Wace LLP Takes Position in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Inc. Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor - Marketscreener.com
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise - Simply Wall St
XTX Topco Ltd Makes New Investment in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics reports promising trial results for cancer drug - Investing.com India
Investing in Repare Therapeutics Inc (RPTX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Repare Therapeutics Inc (RPTX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Press Release Service: Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - CRISPR Medicine News
Repare Therapeutics reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - BioSpace
Stocks to Watch: CVS Health, PepsiCo, Repare Therapeutics - MarketWatch
Repare Therapeutics Gets Encouraging Early Phase 1 Data for Camonsertib - MarketWatch
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Blue Owl Capital Holdings LP - MarketBeat
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company - Yahoo Finance
Replimune Group (NASDAQ:REPL) Stock Price Up 3.8% on Analyst Upgrade - MarketBeat
Financial Metrics Unveiled: Replimune Group Inc (REPL)’s Key Ratios in the Spotlight - The Dwinnex
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Public Employees Retirement Association of Colorado - Defense World
DNA Repair Drugs Market Freshly Published Findings Size, Key Manufacturers, Demand Analysis, Share And Over... - WhaTech
WORK Medical Technology Group LTD Ordinary Shares' Quiet Period Set To End on October 2nd (NASDAQ:WOK) - MarketBeat
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment - openPR
Silexion reports improved outcomes in pancreatic cancer trial - Investing.com India
A stock that deserves closer examination: Replimune Group Inc (REPL) - US Post News
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer - StockTitan
Repare Therapeutics keeps Buy rating, stock target on updated trial results - Investing.com Canada
Repare Therapeutics reports key biomarkers linked to ovarian, endometrial cancer prognosis - Investing.com
Press Release Service: Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers - CRISPR Medicine News
RPTXRepare Therapeutics Inc. Common Shares Latest Stock News & Market Updates - StockTitan
Repare Therapeutics' (RPTX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Receives Buy Rating from HC Wainwright - Defense World
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers - The Bakersfield Californian
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of “Buy” from Analysts - Defense World
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):